VERA THERAPEUTICS INC CLASS A (VERA)
Sector: Health Care
2026 Annual Meeting Analysis
VERA THERAPEUTICS INC CLASS A · Meeting: May 21, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class II Directors to Hold Office Until the 2029 Annual Meeting of Stockholders
VERA's 3-year total return of +474% vastly outperforms the XBI (SPDR S&P Biotech ETF) by +400 percentage points, far exceeding the 65-point threshold required to trigger an against vote; Dr. Morrissey also serves as a sitting CEO of Exelixis and holds this one outside public board seat, which is within the policy limit of two outside seats for a sitting CEO.
No TSR trigger fires given VERA's exceptional 3-year outperformance versus the XBI (SPDR S&P Biotech ETF); Mr. Enright holds seats on Jazz Pharmaceuticals, BioAge Labs, and Zenas Biopharma plus VERA — four total public boards — which is at but not over the four-board limit, and he is a non-executive director (not a sitting CEO), so no overboarding flag applies.
Mr. Meyers was appointed to the Board in November 2025, which is less than 24 months before the meeting date, making him fully exempt from the TSR underperformance trigger; he brings extensive biopharmaceutical commercial leadership experience and no other policy flags apply.
All three Class II director nominees receive a FOR vote. VERA's 3-year stock return of +474% dramatically outpaces the XBI (SPDR S&P Biotech ETF) benchmark by +400 percentage points, well above the 65-point threshold needed to trigger concerns, so the TSR test does not flag any nominee. No overboarding, attendance, independence, or familial relationship issues were identified. Mr. Meyers is additionally exempt as a director appointed less than 24 months ago.
Say on Pay
✓ FORCEO
Marshall Fordyce, M.D.
Total Comp
$6,986,410
Prior Support
97%%
The CEO's total compensation of approximately $7.0 million is reasonable for a clinical-stage biotech CEO at a $2.9 billion company, and the pay structure is appropriately weighted toward variable pay — base salary of $660,000 represents only about 9% of total compensation, with the large majority delivered through stock options and restricted stock units that vest over four years and are inherently tied to stock price performance. The annual cash bonus was paid at 140% of target, which is above the baseline but justified given meaningful clinical milestones achieved in 2025 (FDA priority review granted and positive Phase 3 trial results published in the New England Journal of Medicine), and VERA's 3-year stock return of +474% substantially outperforms the XBI (SPDR S&P Biotech ETF), confirming that above-target incentive pay is aligned with shareholder outcomes. The prior year say-on-pay vote received 97% support, the company maintains a clawback policy compliant with SEC rules, and no governance red flags such as guaranteed bonuses, tax gross-ups, or excessive perquisites were identified.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
8 yrs
Audit Fees
$2,028,160
Non-Audit Fees
$20,000
KPMG has audited VERA since 2018 (approximately 8 years), well below the 25-year tenure threshold; non-audit fees of $20,000 represent less than 1% of audit fees of $2,028,160, far below the 50% ratio that would raise independence concerns; and KPMG is a Big 4 firm appropriate for a company of VERA's $2.9 billion market cap.
Overall Assessment
The 2026 Vera Therapeutics annual meeting presents three standard proposals — director elections, auditor ratification, and say-on-pay — all of which receive a FOR vote under this policy. VERA has delivered exceptional shareholder returns (+474% over three years vs. +74% for the XBI, the SPDR S&P Biotech ETF), its auditor relationship is appropriately sized and independent, and its executive pay program is well-structured with strong variable pay components tied to meaningful clinical and operational milestones.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing